MX2010007742A - Preparacion y separacion enantiomerica de 7-(3-piridinil)-1,7-diaz aspiro[4,4]nonano y formas de sal novedosas del racemato y enantiomeros. - Google Patents

Preparacion y separacion enantiomerica de 7-(3-piridinil)-1,7-diaz aspiro[4,4]nonano y formas de sal novedosas del racemato y enantiomeros.

Info

Publication number
MX2010007742A
MX2010007742A MX2010007742A MX2010007742A MX2010007742A MX 2010007742 A MX2010007742 A MX 2010007742A MX 2010007742 A MX2010007742 A MX 2010007742A MX 2010007742 A MX2010007742 A MX 2010007742A MX 2010007742 A MX2010007742 A MX 2010007742A
Authority
MX
Mexico
Prior art keywords
nonane
pyridinyl
diazaspiro
salts
preparation
Prior art date
Application number
MX2010007742A
Other languages
English (en)
Inventor
Gregory J Gatto
Julio A Munoz
John Genus
Gary Maurice Dull
Jacob Mathew
Inigo Pfeiffer
Jessica Beaver
Scott Breining
Steve M Toler
James Wamsley
Jianxun Xie
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of MX2010007742A publication Critical patent/MX2010007742A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se ha desarrollado una síntesis escalable novedosa para la preparación de 7-(3-piridinil)-1,7-diazaespiro[4.4]nonano, y se han formado sales de 7-(3-piridinil)-1,7-diazaespiro[4.4]nonano con ácido succínico y ácido oxálico; además, 7-(3-piridinil)-1,7-d iazaespiro[4.4]nonano se ha separado en sus estereoisómeros por resolución con ácidos L y D di-p-toluoiltartáricos, dando (R)- y (S)-7-(3-piridinil)-1,7-diazaespiro[4.4]nonano de pureza enantiomérica alta; se han preparado numerosas sales sólidas del (R)- y (S)-7-(3-piridinil)-1,7-diazaespiro[4.4]nonato resultante; se describen métodos para la preparación de las sales racémicas y enantioméricas, composiciones farmacéuticas que comprende dichas sales, y usos de las mismas; las sales se pueden administrar a pacientes susceptibles a condiciones y trastornos o que los padecen, tales como trastornos del sistema nervioso central, para tratar y/o prevenir dichos trastornos.
MX2010007742A 2008-01-15 2009-01-15 Preparacion y separacion enantiomerica de 7-(3-piridinil)-1,7-diaz aspiro[4,4]nonano y formas de sal novedosas del racemato y enantiomeros. MX2010007742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2119708P 2008-01-15 2008-01-15
PCT/US2009/000242 WO2009091561A1 (en) 2008-01-15 2009-01-15 Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers

Publications (1)

Publication Number Publication Date
MX2010007742A true MX2010007742A (es) 2010-08-06

Family

ID=40885603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007742A MX2010007742A (es) 2008-01-15 2009-01-15 Preparacion y separacion enantiomerica de 7-(3-piridinil)-1,7-diaz aspiro[4,4]nonano y formas de sal novedosas del racemato y enantiomeros.

Country Status (15)

Country Link
US (1) US20110118239A1 (es)
EP (1) EP2242364A4 (es)
JP (1) JP2011509933A (es)
KR (1) KR20100118113A (es)
CN (1) CN101951773A (es)
AU (1) AU2009205720A1 (es)
BR (1) BRPI0907222A2 (es)
CA (1) CA2712141A1 (es)
CO (1) CO6280577A2 (es)
EC (1) ECSP10010397A (es)
IL (1) IL206867A0 (es)
MX (1) MX2010007742A (es)
RU (1) RU2010133976A (es)
WO (1) WO2009091561A1 (es)
ZA (1) ZA201005284B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104610146A (zh) * 2015-01-23 2015-05-13 常州大学 一种3-氮杂二环[5,1,0]-7-醛及合成方法
CN104628677A (zh) * 2015-03-16 2015-05-20 浙江大学 一种沃替西汀有机酸盐晶型及其制备方法
KR20170119447A (ko) * 2016-04-19 2017-10-27 주식회사 아미노로직스 Dl-4,4'-바이페닐알라닌 알킬에스터로부터 d-4,4'-바이페닐알라닌 알킬에스터 또는 l-4,4'-바이페닐알라닌 알킬에스터를 제조하는 방법
CN106008316B (zh) * 2016-06-17 2018-04-27 成都百事兴科技实业有限公司 一种合成雷迪帕韦手性中间体的方法
US20190124313A1 (en) 2017-10-19 2019-04-25 Intel Corporation Three dimensional glasses free light field display using eye location
CA3109210A1 (en) * 2018-09-28 2020-04-02 Celltrion, Inc. Novel method for preparing (-)-cibenzoline succinate
WO2020067683A1 (en) * 2018-09-28 2020-04-02 Celltrion Inc. Novel process for the preparation of (+)-cibenzoline succinate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852041A (en) * 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en) * 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5604231A (en) * 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5952339A (en) * 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US20020056084A1 (en) * 2000-03-15 2002-05-09 Harris Glen Mclean Active media content access system
GB0030171D0 (en) * 2000-12-11 2001-01-24 Cipla Ltd Process for preparing isomers of salbutamol
IL165829A0 (en) * 2002-07-05 2006-01-15 Targacept Inc N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
GB2403003B (en) * 2003-06-19 2006-06-07 Dek Int Gmbh Inspection system for and method of inspecting deposits printed on workpieces
NZ552792A (en) * 2004-08-20 2009-12-24 Targacept Inc The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds

Also Published As

Publication number Publication date
KR20100118113A (ko) 2010-11-04
BRPI0907222A2 (pt) 2015-07-14
CA2712141A1 (en) 2009-07-23
CN101951773A (zh) 2011-01-19
EP2242364A4 (en) 2011-09-21
RU2010133976A (ru) 2012-02-27
JP2011509933A (ja) 2011-03-31
US20110118239A1 (en) 2011-05-19
ZA201005284B (en) 2011-03-30
CO6280577A2 (es) 2011-05-20
AU2009205720A1 (en) 2009-07-23
WO2009091561A1 (en) 2009-07-23
IL206867A0 (en) 2010-12-30
EP2242364A1 (en) 2010-10-27
ECSP10010397A (es) 2010-09-30

Similar Documents

Publication Publication Date Title
MX2010007742A (es) Preparacion y separacion enantiomerica de 7-(3-piridinil)-1,7-diaz aspiro[4,4]nonano y formas de sal novedosas del racemato y enantiomeros.
JP4759649B2 (ja) 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
JP5852611B2 (ja) （２ｓ，３ｒ）−ｎ−（２−（（３−ピリジニル）メチル）−１−アザビシクロ［２．２．２］オクタ−３−イル）ベンゾフラン−２−カルボキサミド、その新規塩形態およびその使用方法
US7001900B2 (en) Azabicyclic compounds for the treatment of disease
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
NZ592823A (en) Spirocyclic lactams for treating neurodegenerative and/or neurological disorders
CN101636384A (zh) D-氨基酸氧化酶的抑制剂
SA95160370B1 (ar) مركبات سبيرو-أزا ثنائية الحلقات Spiro -azabicyclic مفيدة في العلاج
BR112015014010A2 (pt) peptídeos como agonistas oxitocina
US20070161628A1 (en) Phosphodiesterase inhibitors
US20110313164A1 (en) Lithium derivatives of pyrroloquinoline quinone and preparation method thereof
UA114405C2 (uk) Феніл-3-азабіцикло[3.1.0]гекс-3-илметанони та їх застосування як лікарського засобу
WO2006053039A3 (en) Hydroxybenzoate salts of metanicotine compounds
JP2005522468A (ja) 強力なα２−アドレナリン作用性レセプターの拮抗薬としての多環式化合物
JP2014524482A (ja) 神経変性疾患を処置する組成物及び方法
TW201202251A (en) Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof
CA2768940C (en) Isoform selective phospholipase d inhibitors
MY165623A (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN102617327B (zh) 右旋布洛芬化合物及其制法
CN102686595A (zh) 作为α-7 烟碱乙酰胆碱受体配体的氮杂二环化合物
WO2001089505A1 (de) Verwendung substituierter 1-amino-5-phenylpentan-3-ol- und/oder 1-amino-6-phenylheyan-3-ol-verbindungen als arzneimittel
CN109666013B (zh) 双哌啶取代的异黄酮化合物及其用途
KR20080110152A (ko) 세로토닌 5-ｈｔ₃ａ 길항적 효과를 갖는 피라졸 유도체함유 약제 조성물
AU2015355612A1 (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders